ArticleBiomaterials2018
Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines.
Abstract read
In one paragraph
Article in Biomaterials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Cell and tissue engineering in lymph nodes for cancer immunotherapy.Advanced drug delivery reviews · 2020Pooled it
- Controlling timing and location in vaccines.Advanced drug delivery reviews · 2020Pooled it
- A trivalent gastric cancer antigen conjugated to a diphtheria toxin epitope synergizes with an NKT cell agonist to boost antitumor immunity.Frontiers in immunology · 2026Article
- Biomaterials nanoplatform-based tumor vaccines for immunotherapy.Bioactive materials · 2025Review
- Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment.Molecules (Basel, Switzerland) · 2024Review
- Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines.BME frontiers · 2024Article
- Nasal mRNA Nanovaccine with Key Activators of Dendritic and MAIT Cells for Effective Against Lung Tumor Metastasis in Mice Model.International journal of nanomedicine · 2024Article
- Engineering endosomolytic nanocarriers of diverse morphologies using confined impingement jet mixing.Nanoscale · 2023Article
- Multi-antigen spherical nucleic acid cancer vaccines.Nature biomedical engineering · 2023Article
- Nanocarriers for cancer nano-immunotherapy.Drug delivery and translational research · 2023Review
- Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy.Pharmaceutics · 2023Review
- Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy.Molecules (Basel, Switzerland) · 2023Review
- Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model.International journal of nanomedicine · 2023Article
- Patient-derived xenografts or organoids in the discovery of traditional and self-assembled drug for tumor immunotherapy.Frontiers in oncology · 2023Review
- Dual-Responsive Glycopolymers for Intracellular Codelivery of Antigen and Lipophilic Adjuvants.Molecular pharmaceutics · 2022Article
- Hyaluronic Acid within Self-Assembling Nanoparticles: Endless Possibilities for Targeted Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2022Review
- Bioinspired vaccines to enhance MHC class-I antigen cross-presentation.Current opinion in immunology · 2022Review
- A Potent Micron Neoantigen Tumor Vaccine GP-Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Feng QiuDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN 37235, USA; Laboratory of Anaesthesia and Critical Care Medicine, Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Kyle W BeckerDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN 37235, USA.
Frances C KnightDepartment of Biomedical Engineering, Vanderbilt University, USA.
Jessalyn J BaljonDepartment of Biomedical Engineering, Vanderbilt University, USA.
Sema SevimliDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN 37235, USA.
Daniel ShaeDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN 37235, USA.
Pavlo GilchukDepartment of Pathology, Microbiology and Immunology, School of Medicine, Vanderbilt University, USA; Department of Veterans Administration Tennessee Valley Healthcare System, USA.
Sebastian JoyceDepartment of Pathology, Microbiology and Immunology, School of Medicine, Vanderbilt University, USA; Department of Veterans Administration Tennessee Valley Healthcare System, USA.
John T WilsonDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN 37235, USA; Department of Biomedical Engineering, Vanderbilt University, USA; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, USA. Electronic address: john.t.wilson@vanderbilt.edu.
Vanderbilt University · USSichuan University · CNVA Tennessee Valley Healthcare System · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MMolecular Basis of CD1D and Natural Killer T Cell FunctionR01AI137082 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOYCE, SEBASTIAN · 2019 to 2022
$2.1MProcessing and Presentation of Minor Histocompatibility Antigens that Cause GvHDR01HL121139 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOYCE, SEBASTIAN · 2014 to 2017
$1.6MEngineered Nanoparticles for Protective Subunit Vaccine Delivery and DiscoveryR21AI121626 · NIAID · VANDERBILT UNIVERSITY · PI WILSON, JOHN TANNER · 2016 to 2017
$418kBLRD Research Career Scientist Award ApplicationIK6BX004595 · VA · VETERANS HEALTH ADMINISTRATION · PI JOYCE, SEBASTIAN · 2019 to 2025
–Vaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and AdjuvantI01BX001444 · VA · VETERANS HEALTH ADMINISTRATION · PI JOYCE, SEBASTIAN · 2014 to 2022
–BLRD VA I01 BX001444BLRD VA IK6 BX004595NCI NIH HHS P30 CA068485NHLBI NIH HHS R01 HL121139NIAID NIH HHS R01 AI137082NIAID NIH HHS R21 AI121626NIDDK NIH HHS P30 DK058404
Abstract
Cancer vaccines targeting patient-specific tumor neoantigens have recently emerged as a promising component of the rapidly expanding immunotherapeutic armamentarium. However, neoantigenic peptides typically elicit weak CD8
Indexed as
AcrylatesAdministration, IntranasalAnimalsAntigen PresentationCancer VaccinesCD8-Positive T-LymphocytesCell LineDendritic CellsHistocompatibility Antigens Class IHumansLung NeoplasmsMaleMelanomaMiceMice, Inbred C57BLNanoconjugatesAcrylatesCancer VaccinesHistocompatibility Antigens Class INanoconjugatesPeptidesPolymerspoly(propyl acrylic acid)Antigen cross-presentationCancer immunotherapyEndosomal escapeNanoparticlePeptide antigenVaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.